GTMRx Institute, supported by Johnson & Johnson, American College of Clinical Pharmacy (ACCP), Medecision and the countries largest primary care organization, sponsors and supports multi-stakeholder activities that will encourage practice transformation, create pathways for dissemination of evidence and innovation and encourage payment and policy reform in order to: Advance acceptance and recognition by providers and payors (to include employers) of the importance of creating a systematic, evidence-based approach to medications and their rational use; Engage physicians, clinical pharmacists and other team members who share a complete commitment to medication optimization by providing tools, data, practice standards and implementation resources to advance their ability to optimize medication use in their own settings; and, educate and inform patient groups, Congress, CMS and payors (to include national health systems such as the VA). The goal of the GTMRx Institute is to ensure appropriate and personalized use of medication and genetic therapies by advancing to a scientific, evidence-based and cost effective decision-making process and a team-based, systematic approach to medication use. The GTMRx Institute is co-located with GTMRx Foundation, a not-for-profit organization.
